A Neonate With Petechiae and a Platelet Count of 18,000
A term neonate is noted at 12 hours of life to have scattered petechiae over the trunk and a platelet count of 18,000/µL. The mother is a 32-year-old gravida 3, para 2 with no history of bleeding or thrombocytopenia; her platelet count at delivery was 210,000/µL. The infant is otherwise well, feeding, with no hepatosplenomegaly and no dysmorphism. The team is considering platelet transfusion and asks whether this could be alloimmune thrombocytopenia and whether maternal testing is needed.
1. What is the differential diagnosis for severe neonatal thrombocytopenia at 12 hours, and how do you prioritize it?
Read the worked answer
Differential for early severe neonatal thrombocytopenia:
- Neonatal alloimmune thrombocytopenia (NAIT) - maternal sensitization to paternal platelet antigens (most commonly HPA-1a); mother's platelet count is normal; infant is otherwise well. This is a leading cause of severe isolated thrombocytopenia in a well-appearing term infant.
- Immune thrombocytopenia from maternal ITP - maternal platelet count is usually low; here it is normal, making this less likely.
- Sepsis, TORCH infections, DIC - the infant is well, no hepatosplenomegaly; still, infection should be considered and screened.
- Congenital/inherited thrombocytopenia (e.g., MYH9-related disease, Wiskott-Aldrich, congenital amegakaryocytic thrombocytopenia) - consider if platelets fail to recover or if there are family history or syndromic features.
- Kasabach-Merritt or large vascular lesions - no lesion described.
- Bone marrow infiltration - unlikely in a well infant without organomegaly.
Prioritization: In a well term infant with isolated severe thrombocytopenia and a normal maternal platelet count, NAIT tops the list. The risk of intracranial hemorrhage (up to 10–20%, sometimes in utero) makes prompt evaluation and treatment important.
2. What testing confirms NAIT, and what are the practical constraints on turnaround?
Read the worked answer
NAIT diagnosis requires demonstrating maternal anti-platelet alloantibodies directed against paternal (and infant) platelet antigens, with genotyping of the parents and infant for HPA antigens (classically HPA-1a/1b). Testing typically requires a reference immunohematology laboratory.
Practical constraints:
- Turnaround is days, while the infant needs treatment now. Do not delay therapy for results.
- Maternal sample must be drawn (serum for antibody, EDTA for genotyping); paternal sample helps define the antigen mismatch.
- Infant sample for genotyping may be limited by small blood volume; cord or buccal DNA can help.
- Crossmatch-compatible platelets: HPA-1a-negative platelets are ideal but often unavailable; random donor platelets may be used urgently, with the understanding that they may be less effective.
A reasonable approach: treat empirically (IVIG and/or HPA-compatible platelets), send maternal and paternal samples, and involve a reference lab early. Document the platelet count response to guide further transfusion.
3. How should platelet transfusion be used here, and what is the rationale for IVIG and steroids?
Read the worked answer
Platelet transfusion is indicated for severe thrombocytopenia with bleeding or very low counts (thresholds vary; often <30,000/µL with bleeding, or <20,000/µL in NAIT given ICH risk). In NAIT, transfused platelets are cleared rapidly by maternal antibody, so HPA-compatible platelets are preferred; if unavailable, give random platelets and reassess.
IVIG (typically 1 g/kg/day for 1–2 days) is used to block Fc-receptor-mediated clearance of antibody-coated platelets and is often first-line in NAIT, especially when compatible platelets are unavailable. Steroids may be added but are less consistently effective and carry risks in neonates.
Key points:
- Do not use maternal platelets (they carry the offending antibody).
- Monitor for ICH with cranial ultrasound if there are neurologic signs or very low counts.
- Counsel the family that future pregnancies are at risk and that antenatal management (maternal IVIG, possible fetal platelet transfusion) is available.
The pathologist/laboratory physician should ensure the blood bank is engaged, that antigen-negative units are sourced, and that the family receives genetic counseling.